Sentinel lymph node biopsy in N0 neck of upper aero-digestive tract Squamous cell carcinoma

ESSAY

SUBMITTED FOR PARTIAL FULFILLMENT OF MASTR DEGREE IN OTOLARYNGOLOGY AND HEAD&NECK SURGERY

By

Ahmed Salah El-Din Ali

Under supervision of

Prof.Dr./Mohamed Magdy Samir

Professor Of Otorhinolaryngology

Faculty of Medicine – Ain Shams University

Dr./ Ossama Hassan Mahmoud

Assistant Professor of Otorhinolaryngology

Faculty of Medicine – Ain Shams University

Dr./ Mohamed Shehata Taha

Assistant Consultant of Otorhinolaryngology

Ain shams university hospitals

Faculty of Medicine

Ain Shams University

2013

Index:

-Introduction	1
-Aim of the work	4
-Cervical lymph node groupsPredictive factors of nodal metastasis	11
-Cervical lymph node assessmentManagement of N0 neck	
-SENTINEL LYMPH NODE CONCEPT	31
- Definition of a Sentinel Node	31
- History	31
- Theoretical bases of SLN detection	33
- Sentinel Lymph Node Biopsy in comparison to other neck dissection methods	
- Advantages of sentinel lymph node biopsy	36
- Morbidity of SLNB versus selective neck dissection	40
- Inclusion and Exclusion Criteria of SLNB	43
- Tracers	47
- Blue dye	47
- Radiocolloids labeling	51
- Fluorescent tracer	56
- Lymphoscintigraphy	62
- Technique	67
- Selection of the node	76

- Frozen Section	78
- The specimen	79
- Histopathology	81
- Molecular Study	91
-Results of different studies on SLNB	93
- Summary	101
- Conclusion	104
- Recommendation	105
- References	106
- Arabic summary	

List of figures:

- Figure 1 : levels and sublevels of the neck for describing the location of cervical lymph nodepage10
- Figure 2 : PET/CT imaging
- Figure 3: Patent Blue V dye
- Figure 4: The peritumoral injection of the radioacitive tracer. 99mTc filtered tir colloid
- Figure 5: Infra red camera system page 60
- Figure 6: Jugulodigastric lymph nodes with fluorescence page 60
- Figure 7: Lymph drainage around the submandibular gland page 61
- Figure 8: Lymphoscintigraphy after the peritumoral injection page 65
- Figure 9: SPECT/CT imagespage 66
- Figure 10: Marking the position of the identified sentinel node on the skin
- Figure 11: Surgeon positions sterile-wrapped head of camera
- Figure 12: Components of the gamma probe page 72
- Figure 13: The handheld gamma probe page 73
- Figure 14: The detection of sentinel node using a handheld gamma probe
- Figure 15: Confirmation of the radioactivity of sentinel nodes ex vivo

- Figure 16: Pathologic and molecular tissue handling and sectioning protocol
- Figure 17: Method of exhaustive fine step sectioning of a sentinel lymph node
- Figure 18: Sentinel lymph node demonstrating micrometastasis at high-power magnification
- Figure 19: squamous carcinoma cells in a lymphatic vessel outside a nodepage 86
- Figure 20: A micrometastasis found in the seventh level of a sentinel node that was clear on initial sectioningpage 87
- Figure 21: AE1/AE3 stained section in a sentinel nodepage 87
Figure 22: Viable tumor deposit in the subcapsular tissue with H&E and AE1/AE3page 88
- Figure 23: Cytokeratin positive cells in a sentinel nodepage 88
Figure 24: A group of nucleated isolated tumor cells stained by AE1/AE3 in a sentinel node
- Figure 25: Micrometastasis in a sentinel lymph nodepage 89
- Figure 26: ECAD high-expressors where predominantly sentinel node negative

List of tables:

-Table(1): Lymph Node Groups Found within the Six Neck Levels and the Six Sublevels
-Table (2): American Joint Committee on Cancer's System for Staging Regional Lymph Nodes (N)
-Table (3): Identification of SLNs in patient with oral cavity SCC by SLNB technique
- Table (4): Identification of SLNs in patient with oral & oropharyngeal SCC by SLNB technique
- Table (5): Identification of SLNs in patient with Laryngeal & hypo-pharyngeal SCC by SLNB technique
- Table (6): Identification of SLNs in patient with upper aerodigestive tract SCC in different sites by SLNB technique
- Table (7): NPV of SLNB in patients with oral cavity SCC
- Table (8): NPV of SLNB in patients with Oral & oropharyngeal SCC Page 98
- Table (9) NPV of SLNB in patients with Laryngeal & hypo-pharyngeal SCC

List of abbreviations

- (18F-FDG PET) 18F-Fluorodeoxyglucose positron emission tomography .
- (ACOSOG) American College of Surgeons Oncology Group
- (AE1/AE3) pancytokeratin antibodies
- (cGRPP) current good radiopharmacy practice
- (cN0) clinical node negative
- (cN+) clinical node positive
- (CT) computed tomography
- (cT1/2) clinical T1/2
- (DW) Diffusion weighted
- (EANM) European Association of Nuclear Medicine
- (ECAD) E-Cadherin
- (ECS) extracapsular spread
- (END) elective neck dissections
- (ENI) elective neck irradiation
- (H&E) Hematoxylin-Eosin
- -(HNC) Head and neck cancers
- -(HNSCC) head and neck squamous cell carcinoma
- (HSA) human serum albumin
- (ICG) indocyanine green

- (IFP) interstitial fluid pressure
- -(IHC) immunohistochemistry
- -(IR) infra red
- (IRS) Intensity Reactivity Score
- (L/T ratio) longitudinal / transverse diameters ratio
- -(LSG) lymphoscintigraphy
- -(MBq) megabecquerel
- (MIP) maximum intensity projection
- (MR) magnetic resonance
- (MRI) magnetic resonance imaging
- (N0) clinically negative neck
- (N+) clinically positive neck
- -(NDII) neck dissection impairment index
- -(NIR) near-infrared
- (NPC) nasopharyngeal carcinoma
- (OCSCC) oral cavity squamous cell carcinoma
- (OCT) optimal cutting temperature.
- (OSCC) oral/oropharyngeal squamous cell carcinoma
- (OSNA) one step nucleic acid
- (pN+) pathological node positive
- (PP) percentage of positive cells

- -(QRT-PCR) quantitative real-time polymerase chain reaction
- (SCC) squamous cell carcinomas
- (SENT) Sentinel Node European Trial
- (SI) staining intensity
- (SLN) sentinel lymph node
- (SLNB) sentinel lymph node biopsy
- (SNB) Sentinel node biopsy
- (SND) selective neck dissection
- (SPECT) single photon emission computed tomography
- (SSS) step serial section
- (STDs) soft tissue deposits
- (Tc99) technetium-99
- (TC-SC) Technetium 99-labelled sulfa colloid
- (TNM system) tumor, node and metastasis system
- (US) ultrasound
- (USgFNAC) ultrasound guided fine needle aspiration cytology
- (VEGF-C) vascular endothelial growth factor C

ACKNOWLEDGMENT

"..الحمد لله الذي هدانا لهذا وما كنا لنهتدي لولا أن هدانا الله.." (

I would like to express my deep gratitude to Professor Dr.Mohamed Magdy Samir, Professor of Otorhinolaryngology, Ain-Shams University, for his helpful and constructive suggestions, and for the continuous encouragement that he generously offered during this work.

I am also very grateful to Dr. Ossama Hassan Mahmoud, Assistant Professor of Otorhinolaryngology, Ain-Shams University for his great and smart guidance and supervision of this work; also he devoted much of his precious time and effort in order to achieve this work in a successful form.

I am also very thankful for Dr. Mohamed Shehata Taha Assistant Consultant of Otorhinolaryngology, Ain shams university hospitals, for his kind supervision and valuable guidance in this work, and for his great effort and encouragement during the work.

Special thanks to my family who helped me and provided me the personal support in completing this work.

AHMED SALAH EL-DIN

Introduction

Head and neck cancers (HNC) are dominated by squamous cell carcinomas originated from the epithelium of the upper aerodiagestive tract. The initial route of metastases is, in most cases, via lymphatics to the regional nodes of the neck. The presence of cervical metastases (N1-N3) is the most important prognostic factor in head and neck cancer patients, reducing the survival to 50% compared with patients without nodal involvement (N0). (1)

Accurate staging at the time of diagnosis is critical for selection of the appropriate treatment strategy. Unfortunately, at the time of initial diagnosis more than 50% of patients already present with regional nodal metastases or even distant metastases.(2) A single tumor-containing node will upstage tumors to at least stage 3, irrespective of primary tumor size. (3)

The clinically negative (N0) neck is defined by its absence of palpable or radiographically suspicious lymph nodes. (4)

The management of N+ head and neck squamous cell carcinoma (HNSCC) is relatively clear-cut. By contrast, the investigation and treatment of patients with clinically N0 disease is controversial. Most institutions electively treat the neck with surgery or radiotherapy because the risk of occult metastases is over 20%, even though it will be unnecessary in the majority of cases. (5)

The problem of identifying microscopic nodal disease is exemplified by the patient who has a primary tumor in the head and neck, but no metastatic cervical adenopathy evident on clinical, computed tomography (CT) and magnetic resonance (MR) examinations (N0 neck by tumor, node and metastasis TNM system). (6)

imaging with computed tomography and/or magnetic Morphologic (MRI) assess the aerodigestive tract resonance imaging provide to information about primary tumor size, infiltration, involvement surrounding structures and regional nodal involvement. (2)

Use of 18F-Fluorodeoxyglucose positron emission tomo-graphy (18F-FDG PET) in head and neck cancer compared to CT indicates that positron emission tomography has a higher sensitivity and specificity for staging cancer. The main drawback of 18F-FDG PET alone is the limitation with respect to lesion localization.(2)

The combined use of these modalities has proven efficacious for cases with diseased nodes larger than 1 cm. They all remain ineffective for the assessment of occult disease (tumor-containing nodes < 1 cm in size), because microscopic metastases of the lymphatics cannot be identified with imaging studies. (3)

By definition, the sentinel lymph node (SLN) is the first draining lymph node to receive lymphatic drainage from a primary tumor of a specific site. In case of lymphatic spread, the lymphatic drain will first pass to the SLN. All following nodes may be reached only subsequently by the disease. (7)

localization of Lymphoscintigraphic the sentinel lymph node combination with ultrasound guided fine needle aspiration cytology (USgFNAC) offers the possibility of detecting occult metastatic disease in patients staged as N0. However, the potential inability of the method to puncture small sentinel nodes and incidental aspiration of micrometastatic material within a node strongly limit the negative predictive value of this method. Thus, it does not seem to be an alternative to biopsy of the SLN. (8)

Some authors have suggested that patients with negative results using the most accurate imaging studies, such as CT or PET-CT, could be candidates to a wait-and-see policy. (9)

It should be kept in mind that the stage at which recurrences are detected is also dependent on the means and intensity of follow-up and may well determine the salvage rates. Salvage surgery was successful in only 24% of patients who presented later with neck metastasis. (10)

Finally, although all these strategies have attempted to avoid unnecessary neck dissections, the number of negative elective neck dissections (END) could still be as high as 80%.(9)

The amount and quality of information currently available does not offer a definitive answer to the question of the prognostic effect of elective neck dissection. Furthermore, the recent introduction of sentinel lymph node biopsy in the diagnosis and treatment of head and neck cancer, has brought back the old question regarding the clinical usefulness of elective neck dissection. (9)

Sentinel node biopsy (SNB) is an alternative to elective neck dissection for the management of T1/T2 NO oral and oro-pharyngeal squamous cell carcinomas and is also finding application to head and neck cancer at other sites. The main clinical aim of sentinel node biopsy is to achieve better staging and there is now evidence that the procedure reduces morbidity (11) . In recent studies using radiotracers, the diagnostic accuracy and the localization rate reaches almost 100%. (12)

Aim of the work:

This work aims at reviewing the literature for the role of sentinel lymph node biopsy in achieving more accurate staging in N0 neck of upper aero-digestive tract squamous cell carcinoma, to avoide false negative results or overtreatment and hence reduce neck dissection- associated morbidity.

Cervical Lymph Node Groups

The patterns of spread of cancer from various primary sites in the head and neck to the cervical lymph nodes have been documented retrospective analysis of large series of patients undergoing dissection. The nodal groups at risk for involvement are widespread throughout the from the mandible and neck, extending superiorly to the clavicle inferiorly and from the posterior triangle of the neck laterally to the midline viscera and then to the contralateral side of the neck. It is now recommended that the lymph node groups in the neck be categorized according to the level system originally described by the Memorial Sloan-Kettering Group (Fig. 1). (13)

Division of Neck Levels By Sublevels

The 2001 report of the American Head and Neck Society's Neck Dissection Committee recommended the use of sublevels for defining selected lymph node groups within levels I, II, and V on the basis of the biologic significance, independent of the larger zone in which they lay. These are outlined in (Fig. 1) as sublevels IA (submental nodes), IB (submandibular nodes), IIA and IIB (together composing the upper jugular nodes), VA (spinal accessory nodes), and VB (transverse cervical and supraclavicular nodes). The boundaries for each of these sublevels are defined in Table 1. (13)

(Table 1.) Lymph Node Groups Found within the Six Neck Levels and the Six Sublevels.

Lymph Node Group	Description
Submental (sublevel I _A)	Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone; these nodes are at the greatest risk of harboring metastases from cancers arising from the floor of the mouth, anterior oral tongue, anterior mandibular alveolar ridge, and lower lip (see Fig.1).